These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38053975)

  • 1. Expanding options of supportive care in IgA nephropathy.
    Maixnerova D; Hartinger J; Tesar V
    Clin Kidney J; 2023 Dec; 16(Suppl 2):ii47-ii54. PubMed ID: 38053975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents for treating IgA nephropathy.
    Kunter U; Seikrit C; Floege J
    Curr Opin Nephrol Hypertens; 2023 Sep; 32(5):418-426. PubMed ID: 37382182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgA nephropathy in adults-treatment standard.
    Gleeson PJ; O'Shaughnessy MM; Barratt J
    Nephrol Dial Transplant; 2023 Oct; 38(11):2464-2473. PubMed ID: 37418237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
    Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and targeted steroids for the treatment of IgA nephropathy.
    Locatelli F; Del Vecchio L; Ponticelli C
    Clin Kidney J; 2023 Dec; 16(Suppl 2):ii40-ii46. PubMed ID: 38053978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory IgA Nephropathy: A Challenge for Future Nephrologists.
    Di Leo V; Annese F; Papadia F; Russo MS; Giliberti M; Sallustio F; Gesualdo L
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgA nephropathy.
    Stamellou E; Seikrit C; Tang SCW; Boor P; Tesař V; Floege J; Barratt J; Kramann R
    Nat Rev Dis Primers; 2023 Nov; 9(1):67. PubMed ID: 38036542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and Treatment of IgA Nephropathy-2023].
    Schimpf J; Kronbichler A; Windpessl M; Zitt E; Eller K; Säemann MD; Lhotta K; Rudnicki M
    Wien Klin Wochenschr; 2023 Aug; 135(Suppl 5):621-627. PubMed ID: 37728647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-immunosuppressive therapies for childhood IgA nephropathy.
    Shima Y; Nakanishi K; Yoshikawa N
    Pediatr Nephrol; 2021 Oct; 36(10):3057-3065. PubMed ID: 33594462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of monoclonal antibodies in the treatment of IgA nephropathy.
    Maixnerova D; Tesar V
    Expert Opin Biol Ther; 2023 May; 23(5):419-427. PubMed ID: 37183663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study.
    Park S; Baek CH; Go H; Kim YH; Min SI; Ha J; Kim YC; Lee JP; Kim YS; Moon KC; Park SK; Lee H
    BMC Nephrol; 2019 Sep; 20(1):354. PubMed ID: 31510954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.
    Tamouza H; Chemouny JM; Raskova Kafkova L; Berthelot L; Flamant M; Demion M; Mesnard L; Paubelle E; Walker F; Julian BA; Tissandié E; Tiwari MK; Camara NO; Vrtovsnik F; Benhamou M; Novak J; Monteiro RC; Moura IC
    Kidney Int; 2012 Dec; 82(12):1284-96. PubMed ID: 22951891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F; Ackermann D; Hilgers RD; Floege J
    J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
    Ferraro PM; Ferraccioli GF; Gambaro G; Fulignati P; Costanzi S
    Nephrol Dial Transplant; 2009 Jan; 24(1):156-60. PubMed ID: 18685141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of IgA nephropathy: an update.
    Rosselli JL; Thacker SM; Karpinski JP; Petkewicz KA
    Ann Pharmacother; 2011 Oct; 45(10):1284-96. PubMed ID: 21954446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges.
    Gutiérrez E; Carvaca-Fontán F; Luzardo L; Morales E; Alonso M; Praga M
    Nephron; 2020; 144(11):555-571. PubMed ID: 32818944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of IgA nephropathy: Recent advances and prospects.
    Coppo R
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S13-S21. PubMed ID: 29606258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy.
    Sun L; Zi X; Wang Z; Zhang X
    BMC Nephrol; 2023 Mar; 24(1):63. PubMed ID: 36949400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.